Trial Profile
An Enriched Enrollment, Double-Blind, Placebo-Controlled, Parallel Group, Randomized Withdrawal Trial to Evaluate the Efficacy, Tolerability and Safety of Etoricoxib (Arcoxia) in Patients With Moderate to Severe Neuropathic Pain
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Etoricoxib (Primary)
- Indications Diabetic neuropathies; Neuropathic pain; Postherpetic neuralgia
- Focus Therapeutic Use
- 24 Jul 2012 Status changed from recruiting to discontinued as reported by EudraCT.
- 28 Dec 2010 New trial record